StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
SPRBSPRUCE BIOSCIENCES, INC.
stockpulse.co.kr
Nasdaq
$44.54▼ 2.26%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $122.6MShares out 2.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

8
  • 8.12Pre-market26.08.12 22:10
    10-QEarnings#●●●#●●●

    SPRUCE BIOSCIENCES, INC.

    Spruce Biosciences entered into a stock purchase agreement on August 7, 2026, for a private placement totaling $5.5 million. Additionally, the company appointed Adrian Quartel as the new Chief Medical Officer, effective July 27, 2026.…more

    $44.54-2.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.12Pre-market26.08.12 22:05
    8-KKey event

    SPRUCE BIOSCIENCES, INC.

    Spruce Biosciences reported a net loss of $16.2 million for the second quarter of 2026 and plans to initiate the BLA submission and TrAnsform confirmatory study for TA-ERT in the fourth quarter of 2026. The company also secured a $5.5 million strategic investment from patient advocacy groups and maintains sufficient cash to fund operations into the second half of 2027.…more

    $44.54-2.26%vs prev close
    View filingShare
  • 8.4After-hours26.08.05 08:51
    SCHEDULE 13G/AOwnership

    SPRUCE BIOSCIENCES, INC.

    밀레니엄 매니지먼트(Millennium Management LLC)와 그 관계사들이 스프루스 바이오사이언스(Spruce Biosciences, Inc.)의 보통주에 대한 공동 보유 지분 공시를 위해 13G 공동 신고 계약을 체결했다. 이번 공시는 2026년 8월 3일자로 작성되었으며, 해당 기관들이 지분 보유 현황을 공동으로 신고함을 확정했다.…more

    $44.54-2.26%vs prev close
    View filingShare

7 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.26Pre-market26.08.26 21:07
    #●●●#●●●

    Spruce Biosciences Launches Online Resource for Sanfilippo Syndrome Type B…more

    Spruce Biosciences has launched a dedicated website to provide information and register interest for its upcoming clinical studies on Sanfilippo Syndrome Type B. Both the expanded access program and the confirmatory study are expected to initiate in the fourth quarter of 2026.…more

    $44.54-2.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.24Pre-market26.08.24 21:02

    ●●●●●●●● ●●●●● ●●●●●●

    Spruce Biosciences has completed two pre-BLA meetings with the FDA, supporting its plan to submit a BLA for Tralesinidase Alfa in late 2026. The FDA indicated that the company's CMC comparability strategies are reasonable.…more

    $44.54-2.26%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →